Sugi Predict

Sugi Predict / Compounds / Berupipam

Berupipam

Berupipam

SCHEMBL2109911

CN1CCc2cc(Cl)c(O)cc2[C@@H](c2cc(Br)cc3c2OCC3)C1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 11/20 0.56
▸ DRD5 P21918 4/20 0.55
▸ DRD2 P14416 3/20 0.55
▸ CYP1A2 P05177 2/20 0.55
▸ CYP2D6 P10635 2/20 0.55
▸ TSHR P16473 2/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ THPO P40225 1/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ SIGMAR1 Q99720 1/20 0.55
▸ LMNA P02545 1/20 0.54
▸ ADRB2 P07550 1/20 0.54
▸ GPR183 P32249 1/20 0.54
▸ APLNR P35414 1/20 0.54
▸ GLP1R P43220 1/20 0.54
▸ CX3CR1 P49238 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Berupipam SCHEMBL29496805 1.00 DRD1 (0.56) DRD1DRD5DRD2CYP1A2CYP2D6
Berupipam SCHEMBL7797350 1.00 DRD1 (0.56) DRD1DRD5DRD2CYP1A2CYP2D6
Berupipam SCHEMBL1229216 0.93 DRD1 (0.62) DRD1DRD5DRD2CYP1A2CYP2D6
SCHEMBL8911525 0.89 DRD1 (0.58) DRD1DRD5DRD2CYP1A2CYP2D6
SCHEMBL8911122 0.88 DRD1 (0.56) DRD1DRD5DRD2CYP1A2CYP2D6
SCHEMBL8911502 0.88 DRD1 (0.56) DRD1DRD5DRD2CYP1A2CYP2D6
SCHEMBL8913638 0.86 DRD1 (0.47) DRD1DRD5DRD2CYP1A2CYP2D6
Odapipam SCHEMBL7207803 0.84 DRD1 (0.66) DRD1DRD5DRD2CYP1A2CYP2D6
Odapipam SCHEMBL2056522 0.84 DRD1 (0.66) DRD1DRD5DRD2CYP1A2CYP2D6
SCHEMBL10692948 0.84 DRD1 (0.57) DRD1DRD5DRD2CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
EP-0750616-B1 ACID ADDITION SALTS OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS CENES LTD (GB) 2001-05-30 — — EP claimed
EP-1058551-A1 USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE DISORDERS, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM SCHERING CORPORATION (US) 2000-12-13 — — EP claimed
WO-1999044615-A1 USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM SCHERING CORPORATION (US) 1999-09-10 — — WO claimed
US-5658899-A EXHIBIT ANTIDOPAMINERGIC EFFECTS; USEFUL IN TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM NOVO NORDISK A/S (DK) 1997-08-19 — — US claimed
EP-0750616-A1 ACID ADDITION SALTS OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS NOVO NORDISK A/S (DK) 1997-01-02 — — EP claimed
WO-1995025102-A1 ACID ADDITION SALTS OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS NOVO NORDISK A/S (DK) 1995-09-21 — — WO claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 — — US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 — — US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 — — US disclosed
US-20150164911-A1 Fused Benzazepines for Treatment of Tourette's Syndrome HORIZON TECHNOLOGY FINANCE CORPORATION 2015-06-18 — — US disclosed
EP-0750616-A1 ACID ADDITION SALTS OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS NOVO NORDISK A/S (DK) 1997-01-02 — — EP disclosed
EP-0750616-A1 ACID ADDITION SALTS OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS NOVO NORDISK A/S (DK) 1997-01-02 — — EP disclosed
WO-1996016046-A2 NOVEL BENZYL PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 1996-05-30 — — WO disclosed
WO-1995025102-A1 ACID ADDITION SALTS OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS NOVO NORDISK A/S (DK) 1995-09-21 — — WO disclosed
WO-1995025102-A1 ACID ADDITION SALTS OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS NOVO NORDISK A/S (DK) 1995-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150164911-A1 Fused Benzazepines for Treatment of Tourette's Syndrome COMT, SLC6A3, HTR3A DRD1 30/4885DRD5 39/4885DRD2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.